Beijing Leadman Biochemistry Co.,Ltd. (SZSE: 300289)
Health Care · Biotechnology · CN
CN¥5.94
-0.67% today · -34.6% 1Y
Beijing Leadman Biochemistry Co.,Ltd. (SZSE: 300289) operates in the Biotechnology industry within the Health Care sector. The company is valued at $480.70M and employs 420 people.
Over the last twelve months the share price has lost 34.6%, trading between 5.19 and 10.41.
Tweenvest scores Beijing Leadman Biochemistry Co.,Ltd. across four factors: quality 70/100, value 28/100, growth 1/100. Its strongest factor is quality.
300289 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $480.70M
- Revenue (TTM)
- $46.08M
- P/E
- —
- EPS
- -0.05
- Dividend yield
- —
- Beta (5Y)
- 0.20
- 52-week high
- CN¥10.41
- 52-week low
- CN¥5.19
- Avg volume (3M)
- —
- Shares outstanding
- 544.01M
- Employees
- 420
- Next earnings
- —
About Beijing Leadman Biochemistry Co.,Ltd.
Beijing Leadman Biochemistry Co.,Ltd. is a prominent entity within the People's Republic of China, specializing in the entire lifecycle – from research and development to manufacturing and distribution – of advanced in vitro diagnostic (IVD) solutions. Its product portfolio encompasses a comprehensive range of biochemical raw materials. This includes critical components like enzymes, coenzymes, antibodies, various buffers, enzyme substrates, culture media, staining reagents, and amino acids. These essential ingredients serve a diverse array of sectors, notably biotechnology, clinical diagnostics, pharmaceutical development, and chemical manufacturing. Beyond raw materials, Leadman also provides specialized biochemistry diagnostic and complementary reagents. Furthermore, the company supplies a sophisticated selection of medical instrumentation. This lineup features the EnigmaML, an automated molecular testing platform designed for both clinical laboratories and various point-of-care settings like clinics and pharmacies. Another key offering is the DiaSys InnovaStar, a compact automated POCT analyzer that delivers laboratory-grade diagnostic accuracy. Customers also benefit from the DiaSys Respons, a versatile random access benchtop analyzer; the CI1000 automatic chemiluminescence immunoassay analyzers; and the IDS-isys, an instrument engineered to boost operational performance and efficiency. Established in 1997, Beijing Leadman Biochemistry maintains its corporate headquarters in Beijing, China.
- ISIN
- CNE100001C22
- Founded
- 1997
- Listed since
- Feb 16, 2012
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $265.43 | +0.18% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.98 | +0.38% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.44 | +0.22% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.78 | +0.13% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $825.89 | -0.98% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $139.44 | -3.88% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.